Jeevan Scientific FY26 profit rises 124% to ₹165.01 lakh
Jeevan Scientific Technology Limited reported a standalone net profit of ₹165.01 lakh for the financial year ended March 31, 2026, a 124% increase from ₹73.57 lakh in the previous year. Revenue from operations for the year rose to ₹5,393.13 lakh from ₹4,360.99 lakh in FY25. For the quarter ended March 31, 2026, the company recorded a standalone net profit of ₹159.48 lakh, a turnaround from a loss of ₹133.71 lakh in the same quarter of the previous year. On a consolidated basis, net profit for the year was ₹103.33 lakh, compared to ₹5.90 lakh in the prior year. The Board of Directors approved the audited financial results, appointed M/s. KP & Associates as Internal Auditors for FY 2026-27, and allotted 1,61,250 equity shares pursuant to the JSTL ESOP Scheme 2016.
*this image is generated using AI for illustrative purposes only.
Jeevan Scientific Technology Limited reported a standalone net profit of ₹165.01 lakh for the financial year ended March 31, 2026, a significant increase from ₹73.57 lakh in the previous year. Revenue from operations for the year rose to ₹5,393.13 lakh from ₹4,360.99 lakh in FY25. The statutory auditors, M/s. Pavuluri & Co., issued an audit report with an unmodified opinion on the financial results.
Financial Performance
For the quarter ended March 31, 2026, the company recorded a standalone net profit of ₹159.48 lakh, a turnaround from a loss of ₹133.71 lakh in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹1,837.73 lakh, compared to ₹892.48 lakh in Q4FY25. On a consolidated basis, net profit for the year was ₹103.33 lakh, compared to ₹5.90 lakh in the prior year, while revenue increased to ₹6,153.71 lakh from ₹4,684.36 lakh.
Standalone Financial Results (₹ in Lakhs)
| Particulars | Year Ended March 31, 2026 | Year Ended March 31, 2025 |
|---|---|---|
| Revenue from operations | 5,393.13 | 4,360.99 |
| Total income | 5,511.91 | 4,423.90 |
| Total expenses | 5,247.97 | 4,346.86 |
| Profit for the year | 165.01 | 73.57 |
| Earnings per share (Basic) | 0.83 | 0.47 |
Board Decisions
The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. Additionally, the Board appointed M/s. KP & Associates, Chartered Accountants, as Internal Auditors for FY 2026-27. The company also granted 4,80,000 stock options to eligible employees pursuant to the JSTL ESOP Scheme 2016.
ESOP Allotment
Pursuant to the exercise of options under the JSTL ESOP Scheme 2016, the company allotted 1,61,250 equity shares of ₹10 each to eligible employees. The total issued share capital post-allotment stands at 2,00,80,215 equity shares. The shares were allotted on May 29, 2026, and rank pari passu with existing shares.
Historical Stock Returns for Jeevan Scientific Technology
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.30% | +0.56% | +2.17% | +35.49% | +106.45% | -8.91% |
What strategic initiatives drove the substantial revenue growth and quarterly turnaround?
How will the recent ESOP allotment impact employee retention and future equity dilution?
Can Jeevan Scientific sustain this profit momentum into the next fiscal year?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
